PMID- 16250265
OWN - NLM
STAT- MEDLINE
DCOM- 20060120
LR  - 20220223
IS  - 0160-9289 (Print)
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Linking)
VI  - 28
IP  - 9
DP  - 2005 Sep
TI  - Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of 
      interleukin-18 and matrix metalloproteinase-9 in patients with 
      hypercholesterolemia.
PG  - 423-8
AB  - BACKGROUND: Interleukin-18 (IL-18), a novel proinflammatory marker, and matrix 
      metalloproteinase-9 (MMP-9) represent the indices of plaque stability. It is 
      unknown whether hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 
      (statins), which provide anti-inflammatory and endothelium protection effects, 
      have the property of stabilizing plaque in patients with hypercholesterolemia. 
      HYPOTHESIS: The study was designed to investigate the influence of statin therapy 
      in circulating IL-18, MMP-9, and endothelial function. METHODS: We investigated 
      the effects of a 12-week therapy with fluvastatin on IL-18, MMP-9, and 
      endothelial function in patients with hypercholesterolemia. RESULTS: Compared 
      with placebo, fluvastatin significantly improved flow-mediated vasodilatation to 
      hyperemia, a hallmark of endothelial function [from 3.8% (-3.9 approximately 
      15.2) to 5.9% (-0.3 approximately 13.2), p = 0.001], and attenuated plasma levels 
      of high sensitivity C-reactive protein (hsCRP) [from 1.3 (0.3 approximately 7.7) 
      to 1.1 mg/l (0.2 approximately 3.5), p = 0.018], IL-18 [from 247.6 (145.4 
      approximately 378.4) to 196.4 pg/dl (90.7 approximately 380.2), p <0.001], total 
      MMP-9 (from 58 +/- 46.3 to 39.4 +/- 22.4 ng/dl, p = 0.023), and MMP-9 activity 
      [from 6.4 (3.6 approximately 27) to 5.6 ng/dl (3.1 approximately 13.7)]. However, 
      no significant correlation was found between the degree of changes in lipid 
      profile and flow-mediated dilatation (FMD) and plasma concentration of IL-18 and 
      MMP-9. CONCLUSIONS: Fluvastatin reduced plasma concentrations of IL-18 and MMP-9, 
      and improved endothelial function in patients with hypercholesterolemia 
      independent of its lipid-lowering effect.
FAU - Leu, Hsin-Bang
AU  - Leu HB
AD  - National Yang-Ming University, School of Medicine.
FAU - Chen, Jaw-Wen
AU  - Chen JW
FAU - Wu, Tao-Cheng
AU  - Wu TC
FAU - Ding, Yu-An
AU  - Ding YA
FAU - Lin, Shing-Jong
AU  - Lin SJ
FAU - Charng, Min-Ji
AU  - Charng MJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Indoles)
RN  - 0 (Interleukin-18)
RN  - 4L066368AS (Fluvastatin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Aged
MH  - Anticholesteremic Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - C-Reactive Protein/drug effects/metabolism
MH  - Cholesterol, LDL/drug effects/metabolism
MH  - Double-Blind Method
MH  - Endothelium, Vascular/drug effects/metabolism/physiopathology
MH  - Fatty Acids, Monounsaturated/*therapeutic use
MH  - Female
MH  - Fluvastatin
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Hypercholesterolemia/*blood/drug therapy
MH  - Indoles/*therapeutic use
MH  - Interleukin-18/*blood
MH  - Male
MH  - Matrix Metalloproteinase 9/*blood/drug effects
MH  - Middle Aged
MH  - Treatment Outcome
MH  - Vasodilation/drug effects
PMC - PMC6654498
EDAT- 2005/10/28 09:00
MHDA- 2006/01/21 09:00
PMCR- 2006/12/05
CRDT- 2005/10/28 09:00
PHST- 2005/10/28 09:00 [pubmed]
PHST- 2006/01/21 09:00 [medline]
PHST- 2005/10/28 09:00 [entrez]
PHST- 2006/12/05 00:00 [pmc-release]
AID - CLC4960280907 [pii]
AID - 10.1002/clc.4960280907 [doi]
PST - ppublish
SO  - Clin Cardiol. 2005 Sep;28(9):423-8. doi: 10.1002/clc.4960280907.